ArticleDrug design, development and therapy2026
Untargeted Metabolomics Investigating the Intracellular Metabolic Alterations of HaCaT Cells Treated with Isotretinoin.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isotretinoin has been increasingly utilized for various dermatological diseases.However, the mechanism of action of isotretinoin on the skin, particularly the epidermis, remains unclear. Purpose: This study aimed to investigate the intracellular metabolic alterations induced by isotretinoin in HaCaT cells. Methods: HaCaT cells were divided into three groups: Group A (control group), Group B(treated with 10 μM isotretinoin for 48 h), and Group C (treated with 10 μM isotretinoin for 7 d). An untargeted metabolomics analysis was employed using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-Q-TOF/MS). Multivariate data analyses were employed to identify distinguishing metabolites, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) was utilized to assess potential metabolic pathways. Results: Isotretinoin inhibited the proliferation of HaCaT cells in a dose-dependent manner. The OPLS-DA model displayed clear segmentation between the Group B and Group A, as well as between Group C and Group A. Compared to Group A, there were 115 significantly differentially metabolites in Group B, including glycerophosphocholine,adenosine,acetylcarnitine,creatine,Dl-lactate,hypoxanthine,uracil,LPC 18:1,creatine phosphate,5'-S-Methyl-5'-thioadenosine. In Group C, there were 140 significantly differentially expressed metabolites compared to Group A, including glycerophosphocholine, niacinamide, creatine, phytosphingosine, oleic acid, hypoxanthine, 1-Palmitoyl-sn-glycero-3-phosphocholine, Dl-lactate, 5'-S-Methyl-5'-thioadenosine and NG,NG-Dimethyl-L-arginine.A total of 30 metabolic pathways were significantly changed (p < 0.05) in Group A and Group B.The most significant metabolic pathways included purine metabolism,nucleotide metabolism,ABC transporters, and the taurine and hypotaurine metabolism signaling pathway. Additionally, 46 metabolic pathways were significantly altered (p < 0.05) in Group A and Group C, with the most significant pathways being nucleotide metabolism, ABC transporters, purine metabolism, and glycerophospholipid metabolism. Conclusion: Important metabolites and metabolic pathways were identified in this study,which will help clarify the underlying mechanism of action of isotretinoin on keratinocytes at the metabolite level and the mucocutaneous adverse effects associated with isotretinoin in the treatment of dermatological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.